Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
5.34 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.263 | 0.259 | 0.264 | 0.056 | 0.096 | 0.071 | 0.038 | 0.036 | 0.019 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.263 | -0.259 | -0.264 | -0.056 | -0.096 | -0.071 | -0.038 | -0.036 | -0.019 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 29.459 | 47.306 | 44.937 | 24.681 | 44.352 | 29.823 | 16.303 | 13.176 | 7.574 | 3.708 | 1.542 | 0.469 | 1.365 |
| General & Administrative Expenses
| 13.335 | 15.374 | 11.283 | 9.985 | 12.155 | 9.876 | 6.186 | 5.52 | 4.415 | 3.563 | 2.135 | 0.645 | 0.744 |
| Selling & Marketing Expenses
| -0.263 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 13.335 | 15.374 | 11.283 | 9.985 | 12.155 | 9.876 | 6.186 | 5.52 | 4.415 | 3.563 | 2.135 | 0.645 | 0.744 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.328 | 0.721 | -21.484 | 0.005 |
| Operating Expenses
| 42.794 | 62.68 | 56.22 | 34.667 | 56.507 | 39.699 | 22.488 | 18.696 | 11.989 | 7.271 | 3.676 | 1.114 | 2.109 |
| Operating Income
| -42.794 | -62.68 | -56.22 | -36.421 | -63.074 | -39.699 | -22.488 | -18.696 | -11.989 | -7.271 | -3.676 | -1.114 | -2.109 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 5.252 | 0.655 | -1.557 | -1.612 | 0.938 | 0.806 | 0.148 | -0.003 | -0.101 | 2.328 | 16.896 | -21.618 | 0.005 |
| Income Before Tax
| -37.543 | -62.025 | -57.776 | -38.033 | -62.137 | -38.893 | -22.341 | -18.699 | -12.09 | -5.187 | 13.06 | -23.075 | -2.378 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | -0.655 | 1.478 | -0.479 | -1.31 | 0.953 | 0.223 | 0.066 | -0.008 | 0.243 | 0.159 | -21.142 | 0.285 |
| Net Income
| -37.543 | -61.369 | -59.254 | -37.554 | -60.827 | -38.893 | -22.341 | -18.699 | -12.09 | -5.187 | 13.06 | -23.075 | -2.378 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.64 | -1.05 | -1.1 | -1.11 | -2.24 | -1.79 | -1.4 | -1.65 | -1.4 | -1.36 | 39.9 | -5.72 | -7.26 |
| EPS Diluted
| -0.64 | -1.05 | -1.1 | -1.11 | -2.24 | -1.79 | -1.4 | -1.65 | -1.4 | -1.35 | 2.72 | -5.1 | -0.5 |
| EBITDA
| -42.531 | -60.331 | -56.034 | -34.318 | -54.965 | -38.746 | -22.227 | -18.594 | -11.978 | -7.271 | -3.676 | -22.594 | -2.097 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |